key: cord-0826227-rtw8m00s authors: Akula, Shaw M.; McCubrey, James A. title: Where are we with understanding of COVID-19? date: 2020-06-20 journal: Adv Biol Regul DOI: 10.1016/j.jbior.2020.100738 sha: 58a96e01d9d11b1e43f2635961cf4c1febf522f7 doc_id: 826227 cord_uid: rtw8m00s Coronavirus disease 2019 caused by SARS-CoV-2 originated from China and spread across every corner of the world. The scientific interest on COVID-19 increased after WHO declared it a pandemic in the early February of 2020. In fact, this pandemic has had a worldwide impact on economy, health, and lifestyle like no other in the last 100 years. SARS-CoV-2 belongs to Coronaviridae family and causes the deadliest clinical manifestations when compared to other viruses in the family. COVID-19 is an emerging zoonotic disease that has resulted in over 383,000 deaths around the world. Scientists are scrambling for ideas to develop treatment and prevention strategies to thwart the disease condition. In this review, we have attempted to summarize the latest information on the virus, disease, prevention, and treatment strategies. The future looks promising. Coronavirus disease 2019 has resulted in considerable morbidity and mortality globally since December of 2019. The number of COVID-19 infected people around the world has exceeded 3 million, and more than 200,000 people have died and this has had a huge impact on human health and economic development [1] . In less than six months, COVID-19 has managed to spread from a lesser known province of Wuhan in China to almost every country in the world [2] . No wonder did the World Health Organization (WHO) declared COVID-19 as a pandemic [3] . The COVID-19 pandemic has managed to expose our poor sanitation/hygiene worldwide; and almost half of the world has been placed in quarantine [4] . In most cases, quarantine has lasted over 45 days. Severe acute respiratory coronavirus syndrome 2 virus (SARS-CoV-2) causes COVID-19 [5] . SARS-CoV-2 is one of the highly pathogenic coronaviruses to emerge and spread in human populations. The International Committee on Taxonomy of Viruses (ICTV) classified SARS-CoV-2 as a member of the Sarbecovirus subgenus (genus Betacoronavirus) [6, 7] . The animalhuman interface is suspected as the primary source of the emerging zoonotic disease, COVID-19 [8] . Apart from bats, it is too early to rule out the role of intermediate hosts such as snakes, pangolins, turtles, and other wild animals in the origin of SARS-CoV-2 [3, 9] . SARS-CoV-2 is distantly related to Middle East respiratory syndrome Coronavirus (MERS-CoV) when compared to SARS-CoV [2] . Adults seem to be predominantly affected by COVID-19 [10] . The incubation period is about 2 to 14 days between infection and symptom onset [11] . The most common symptoms are fever, cough, dyspnea, and myalgias and/or fatigue. Interestingly, all cases have shown radiographic evidence of pneumonia [12] . In this review, we have attempted to summarize the biology of SARS-CoV-2 in COVID-19 pandemic. The lockdown due to COVID-19 has several ramifications to the society. It has resulted in a major financial crisis resulting in the 'Great Recession' [13] . The disproportionate effects of COVID-19 predominantly in underprivileged communities are a reflection of inequality and social exclusion that exist in our society at large [14] . It has impacted all forms of education globally. Many countries have managed to switch over to online teaching modes [15] . However, several other countries struggle with this mode primarily because of lack of infrastructure, guidance, and poverty. Research in general declined sharply because of restricted work times. Layoffs at various levels in the industries is a major concern that is bound to destabilize individuals and families. Last but not the least are the psychological/social problems associated with social distancing. These will have a severe bearing on the future generation. Intermediate hosts have a special role in the transmission of SARS-CoV-2 based on the following evidences: (i) COVID-19 was associated with seafood and wildlife market in Wuhan [16] ; (ii) SARS-CoV-2 is believed to have originated from the bats [17] ; and (iii) Coronaviruses closely related to SARS-CoV-2 have been isolated from Malayan or Sunda pangolins in China [18] . Genetic analysis has identified 103 commonly circulating strains of SARS-CoV-2; all of which recently shifted to infecting humans [19] . Based on two single nucleotide polymorphism (SNPs), the strains have been classified into two types: L (T28,144 is in the codon of Leucine) and S (C28,144 is in the codon of Serine) types. The virus is easily spread by speech droplets airborne from symptomatic and asymptomatic carriers [20] . Risk factors to COVID-19 may include household plumbing, large family cluster, overcrowding, male sex, comorbidities like hypertension, bullous pemphigoid and pemphigus vulgaris patients, cancer patients, renal disease, glutathione deficiency, race, and socioeconomic status [21] [22] [23] [24] [25] [26] [27] [28] . SARS-CoV-2 possess a positive sense RNA genome expressing open reading frames that encodes both structural and non-structural proteins [29] . The genome length is approximately 29.8kb [30] . Like other coronaviruses, SARS-CoV-2 is an enveloped virus. The key structural proteins include spike (S) [31] , nucleocapsid (N) [32] , membrane (M) [33] , and envelope (E) proteins [34] . The envelope is composed of M and E proteins. The fact that the virus is enveloped makes it susceptible to commonly used detergent and ethanol. The virus entry among the members of Coronaviridae family is a highly conserved process that is mediated by the homotrimer and glycosylated S protein [35] [36] [37] . The envelope is studded with 5-7nm of S protein. Conformational changes to S protein is triggered as soon as receptor binding domain (RBD) within the S1 subunit of S protein interacts with the host cell receptor molecule, angiotensin-converting enzyme 2 (ACE2) [38] . Receptor binding stabilize the binding by shedding of the S1 subunit and transition of the S2 subunit [39] . The S2 subunit of S protein facilitates internalization of the virus [40] . Apart from its role in the virus entry process, it represents a target for antibody-mediated neutralization as it is highly immunogenic; all of which make a good target to design vaccine and therapies. The first manifestation of the SARS-CoV-2 infection are ageusia and anosmia in the patients with COVID-19 infection [41] . The other common manifestations are fever, cough, dyspnea, and myalgias and/or fatigue in COVID-19 patients [12] . However, it is not limited to the above symptoms alone. The other symptoms may include the following: Ataxia, headache, dizziness, and loss of consciousness, which suggest a potential for neural involvement [42] . (ii) Diarrhea [43] . (iii) Subacute thyroiditis (SAT) [44] . (iv) Nausea and vomiting [45] . (v) In severe case, there may be acute respiratory distress syndrome or even multi-organ failure [46] . (vi) Skin manifestations like rashes on the back of trunk, and urticaria [47] . Due to varied symptoms of the disease, it is imperative for the clinician to pay attention while making a diagnosis. According to the current available information, people between the ages of 40 and 60 are more prone to this infection compared to children [48] . These are some of the commonly used predictors of COVID-19 severity: Prevention of a disease is a challenge when it is declared a pandemic. An elaborate study from China concluded the following key approaches to prevent COVID-19 [52]: (i) Identify the source effectively and control the infection: The main source of infection are patients with COVID-19. Medical fraternity must diagnose early, report early, isolate early and start treating the patients early. One other important step is to quarantine those that are suspected of being exposed to the virus or the disease [53] . (ii) Break the transmission cycle: The virus is easily transmitted via aerosol and to lesser extent by feces and urine. The transmission cycle can be halted by following hygienic practices [54, 55] like washing hands, proposer disposal of nasal secretions, appropriately using hand sanitizers, wearing facial masks, and avoiding physical contacts as much as possible. It is also imperative that the local governments always ensure supply of quality drinking water to households. During times of pandemic, hospitals must strengthen inspection and quality of aerosols and disposal of wastes in their facility. (iii) Protection of the vulnerable population: The high-risk population includes the aged, pregnant women, patients in emergency, critically ill, with acute cardiovascular and cerebrovascular diseases, with renal disease, on hemodialysis, diabetic, and ailing with cancers [56] [57] [58] . Medical institutions must pay special attention to the well-being of this population during the pandemic. A pandemic at this level has driven research in identifying nutritional supplements that may have a palliative effect on the outcome of COVID-19 disease. The latest to join the list of potential supplements that may have therapeutic benefits is nicotinamide riboside (NR). NR is supposed to elevate nicotinamide adenine dinucleotide (NAD + ) precursors which is an essential coenzyme for a variety of metabolic pathways [59] . In general, malnutrition is a risk factor for any infection and SARS-CoV-2 infection is not an exception. Dietary supplements like vitamin A, vitamin C, omega-3 fatty acids, polyphenols and carotenoids exert anti-inflammatory and anti-oxidative properties [60] . Supplements like vitamin D may decrease exposure to SARS-CoV-2 by inhibiting expression of ACE-2 [61] ; the known receptor that promotes viral entry [62] . Zinc as a supplement is said to enhance both innate and adaptive immunity and thus inhibit SARS-CoV-2 replication [63] . Again, all these supplements are not without their benefit, but work needs to be done to establish if they can serve as a potential antiviral drug. The most widely used drugs to treat COVID-19 are chloroquine and hydroxychloroquine [64] . The other antiviral drugs that are being prescribed to treat COVID-19 are ribavirin (nucleoside analogue) [65] , remdesivir (nucleotide analogue that inhibit RNA polymerase) [66] , lopinavir/ritonavir (protease inhibitor) [67] , favipiravir (pyrazinecarboxamide derivative known to inhibit RNA polymerase) [68] , antibiotics such as azithromycin and doxycycline [69, 70] , and anti-parasite such as ivermectin [71] . Although, several antivirals are being tested in different combinations, there is no definite, specific, and an efficient monotherapy protocol. The major unsolved issues surrounding the treatment regimen of COVID-19 are Lymphocytopenia, excessive inflammation, and cytokine storm. Albeit, it must be kept in mind that work is on to find the magic bullet and time is of the essence. The current approach to developing a potent vaccine to counter SARS- [72] . Given the short duration of time and the fact that it is an RNA virus capable of mutating rapidly we are not particularly enthusiastic about having a potent and reliable vaccine in the near future. As mentioned earlier, lockdown ensuing this pandemic has destroyed the society economically: people have lost their jobs, businesses closed, drastic changes to education system, and so forth. On the flipside, there has been a dramatic reduction in air pollution [73] , better appreciation for hygienic practices, and a sharp decline in visits to doctors office. Perhaps this pandemic has changed culture-driven behavioral pattern for eternity. We may no longer shake hands, kiss, or hug to greet each other. More importantly, facial masks are here to stay for a long time. Patience is what needs to be practiced. Better prevention and treatment strategies can be developed only when biology of the pathogen is understood. Inhibit SARS-CoV-2 entry by changing glycosylation of ACE2 receptor. Malaria and arthritis. [74] [75] [76] Remdesivir Inhibition of RNA genome replication. Ebola. [77] Lopinavir / ritonavir Protease inhibition HIV. [78] Favipiravir A broad spectrum inhibitor of viral RNA polymerase. Influenza. [79, 80] Azithromycin Interferes with protein synthesis. Bacterial conjunctivitis. [81] Doxycyclin Inhibits bacterial protein synthesis. Antibiotic against gram + and grambacteria. [82] Ivermectin Inhibits importin mediated viral import. Nematode and orthropod parasites. [83] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective COVID-19: animals, veterinary and zoonotic links Empirical Treatment and Prevention of COVID-19 A pneumonia outbreak associated with a new coronavirus of probable bat origin Caution is warranted in using cephamycin antibiotics against recurrent Clostridioides difficile infection Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments The hallmarks of COVID-19 disease novel coronavirus: an emerging global threat A Review of Coronavirus Disease-2019 (COVID-19) Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV The global financial crisis and health equity: early experiences from Canada Social Vulnerability and Racial Inequality in COVID-19 Deaths in Chicago The impact of COVID-19 on the undergraduate medical curriculum Clinical features of patients infected with 2019 novel coronavirus in Wuhan Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins Coronaviruses: origin and evolution The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission American Indian Reservations and COVID-19: Correlates of Early Infection Rates in the Pandemic Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2) Risk factors for mortality in patients with Coronavirus Disease 2019 (COVID-19) in Bolivia: An analysis of the first 107 confirmed cases Bullous skin disease patients in a high-epidemic COVID-19 area Predictors for Severe COVID-19 Infection Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2 RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak Development of multi-specific humanized llama antibodies blocking SARS-CoV /ACE2 interaction with high affinity and avidity. Emerg Microbes Infect Clinical Validation of a SARS-CoV-2 Real-Time Reverse Transcription PCR Assay Targeting the Nucleocapsid Gene The M protein of SARS-CoV: basic structural and immunological properties Immunoinformatic analysis of the SARS-CoV-2 envelope protein as a strategy to assess cross-protection against COVID-19 Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis Structure, Function, and Evolution of Coronavirus Spike Proteins Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction Taste and smell as chemosensory dysfunctions in COVID-19 infection Potential Neuroinvasive Pathways of SARS-CoV-2: Deciphering the Spectrum of Neurological Deficit Seen in Coronavirus Disease 2019 (COVID-19) Clinical Manifestations of Children with COVID-19: a Systematic Review Subacute Thyroiditis After Sars-COV-2 Infection SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19 The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors Plasma albumin levels predict risk for nonsurvivors in critically ill patients with COVID-19 A novel simple scoring model for predicting severity of patients with SARS-CoV-2 infection COVID-19 pandemic: Lessons learned and future directions Hand sanitisers amid CoViD-19: A critical review of alcohol-based products on the market and formulation approaches to respond to increasing demand COVID-19 in Children, Pregnancy and Neonates: A Review of Epidemiologic and Clinical Features COVID-19: is there a link between the course of infection and pharmacological agents in diabetes? The Impact of the COVID-19 Pandemic on Cancer Patients Nicotinamide Riboside-The Current State of Research and Therapeutic Uses Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis Vitamin D receptor activation regulates microglia polarization and oxidative stress in spontaneously hypertensive rats and angiotensin II-exposed microglial cells: Role of reninangiotensin system Two hits to the renin-angiotensin system may play a key role in severe COVID-19 Can Zn Be a Critical Element in COVID-19 Treatment? Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics Favipiravir, an antiviral for COVID-19? Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin Dapsone and doxycycline could be potential treatment modalities for COVID-19 Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19 Rational Vaccine Design in the Time of COVID-19 21-Day Lockdown in India Dramatically Reduced Air Pollution Indices in Lucknow Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Pain over 2 years after start of biological versus conventional combination treatment in early rheumatoid arthritis: results from the randomised controlled SWEFOT trial Smooth or Risky Revisit of an Old Malaria Drug for COVID-19? Hints of hope with remdesivir Brief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral Therapy Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase Antivirals for COVID-19 Impact of a Personalized Audit and Feedback Intervention on Antibiotic Prescribing Practices for Outpatient Pediatric Community-Acquired Pneumonia Doxycycline for exacerbations of chronic obstructive pulmonary disease in outpatients: who benefits? Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance Dear Editor in Chief:We hereby declare that no authors have any conflicts of interest with publication of this manuscript.